Published in J Clin Oncol on January 01, 1998
Gastric cancer. Lancet (2009) 7.27
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology (2013) 2.83
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One (2007) 1.86
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Apoptosis and molecular targeting therapy in cancer. Biomed Res Int (2014) 1.47
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer (2008) 1.39
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia (2010) 1.37
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene (2009) 1.37
Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol (2007) 1.19
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer (2010) 1.19
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer (2008) 1.11
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer (2008) 1.11
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics (2009) 1.09
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J (2011) 1.09
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer (2008) 1.06
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J (2010) 1.04
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer (2006) 1.00
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer (2005) 0.96
Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas. BMC Cancer (2006) 0.95
The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci (2011) 0.94
Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res (2007) 0.93
Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One (2012) 0.92
High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med (2011) 0.91
Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci (2010) 0.90
Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin. Chin J Cancer Res (2011) 0.88
ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol (2008) 0.88
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol (2011) 0.87
Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question. Gastric Cancer (2006) 0.87
Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology (1998) 0.86
Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer (2013) 0.85
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget (2016) 0.85
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomark Insights (2008) 0.85
Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther (2013) 0.85
The herb medicine formula "chong lou fu fang" increases the cytotoxicity of chemotherapeutic agents and down-regulates the expression of chemotherapeutic agent resistance-related genes in human gastric cancer cells in vitro. Evid Based Complement Alternat Med (2011) 0.85
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer (2014) 0.84
Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. Oncologist (2011) 0.82
Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. Exp Ther Med (2010) 0.82
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol (2007) 0.82
Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat (2006) 0.82
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study. Clin Med Oncol (2008) 0.81
Predictive and prognostic markers in colorectal cancer. Gastrointest Cancer Res (2007) 0.81
Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis. J Cancer Res Clin Oncol (2014) 0.81
ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Radiat Oncol (2012) 0.81
Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. Sci Rep (2014) 0.80
YY1 suppresses FEN1 over-expression and drug resistance in breast cancer. BMC Cancer (2015) 0.80
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.80
ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. PLoS One (2015) 0.80
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma. Br J Cancer (2000) 0.79
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. BMC Cancer (2013) 0.78
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat (2010) 0.78
Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy. Int J Clin Exp Med (2015) 0.78
Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. Br J Cancer (2013) 0.78
Biomarkers of head and neck cancer, tools or a gordian knot? Int J Clin Exp Med (2015) 0.78
DNA Repair Pathway Alterations in Bladder Cancer. Cancers (Basel) (2017) 0.77
Factors affecting platinum sensitivity in cervical cancer. Oncol Lett (2015) 0.77
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Oncotarget (2015) 0.77
Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) (2011) 0.76
Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma. Oncol Lett (2017) 0.75
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS One (2014) 0.75
Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901. World J Gastroenterol (2017) 0.75
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci (2017) 0.75
Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin. Exp Ther Med (2016) 0.75
[Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)]. Wien Med Wochenschr (2007) 0.75
Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1. Oncol Lett (2017) 0.75
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75
Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. World J Surg (2017) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics (1989) 19.10
Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A (1989) 18.26
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res (2000) 9.30
Helicobacter pylori. Clin Microbiol Rev (1997) 9.22
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 7.40
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med (1999) 6.16
Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med (1989) 5.78
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ (2001) 5.77
The clinical significance of Campylobacter pylori. Ann Intern Med (1988) 5.08
Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet (1998) 5.02
Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension (1995) 4.35
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci (1995) 4.19
Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med (2000) 3.96
Behçet disease (Behçet syndrome). Semin Arthritis Rheum (1979) 3.88
Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med (1991) 3.86
Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS (1987) 3.78
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res (1999) 3.66
Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1990) 3.65
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Renal function during antihypertensive treatment. Lancet (1995) 3.33
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther (2004) 2.83
Critical care delivery in the intensive care unit: defining clinical roles and the best practice model. Crit Care Med (2001) 2.76
Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res (2000) 2.73
AIDS and self-organization among intravenous drug users. Int J Addict (1987) 2.73
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol (1997) 2.73
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71
Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation (2000) 2.65
C-myc transcript is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment. Nature (1984) 2.63
Helicobacter pylori infection in pernicious anemia: a prospective controlled study. Gastroenterology (1991) 2.57
Anticoagulation in patients with atrial fibrillation. GPs not prepared for monitoring anticoagulation. BMJ (1993) 2.49
Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta (1977) 2.48
Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension (1999) 2.44
Prevention of cell-to-cell spread of herpes simplex virus by leukocytes. J Exp Med (1973) 2.42
Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens (2005) 2.36
Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension (1994) 2.35
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol (2006) 2.34
Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ (1999) 2.31
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res (2001) 2.28
Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol (1999) 2.25
Comparison of direct and indirect solid-phase microradioimmunoassays for the detection of viral antigens and antiviral antibody. Appl Microbiol (1973) 2.23
Guidelines for the clinical use of red cell transfusions. Br J Haematol (2001) 2.21
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Prevention of blinking alters iris configuration in pigment dispersion syndrome and in normal eyes. Ophthalmology (1995) 2.21
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
Epithelial collagens and glycosaminoglycans in the embryonic cornea. Macromolecular order and morphogenesis in the basement membrane. J Cell Biol (1974) 2.18
Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme. BJOG (2013) 2.16
A rapid determination of sodium dodecyl sulfate with methylene blue. Anal Biochem (1975) 2.15
Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol (2000) 2.14
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery (1994) 2.13
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem (1987) 2.07
Comment of N.O.P.H.N. Field Staff on Seattle and Richmond Reports. Am J Public Health Nations Health (1948) 2.06
Methods for managing the increased workload in anticoagulant clinics. BMJ (1996) 2.03
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol (1995) 1.98
Splenectomy for chronic thrombotic thrombocytopenic purpura. Lancet (1990) 1.98